Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Agios Pharmaceuticals (AGIO) Accumulated Depreciation & Amortization (2016 - 2025)

Agios Pharmaceuticals (AGIO) has disclosed Accumulated Depreciation & Amortization for 14 consecutive years, with $60.1 million as the latest value for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 6.4% year-over-year to $60.1 million; the TTM value through Dec 2025 reached $60.1 million, up 6.4%, while the annual FY2025 figure was $60.1 million, 6.4% up from the prior year.
  • Accumulated Depreciation & Amortization hit $60.1 million in Q4 2025 for Agios Pharmaceuticals, up from $56.5 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $60.1 million in Q4 2025 and bottomed at $45.0 million in Q4 2021.
  • Average Accumulated Depreciation & Amortization over 5 years is $52.8 million, with a median of $52.2 million recorded in 2023.
  • Year-over-year, Accumulated Depreciation & Amortization increased 11.33% in 2022 and then rose 4.31% in 2023.
  • Agios Pharmaceuticals' Accumulated Depreciation & Amortization stood at $45.0 million in 2021, then rose by 11.33% to $50.1 million in 2022, then increased by 4.31% to $52.2 million in 2023, then increased by 8.17% to $56.5 million in 2024, then increased by 6.4% to $60.1 million in 2025.
  • According to Business Quant data, Accumulated Depreciation & Amortization over the past three periods came in at $60.1 million, $56.5 million, and $52.2 million for Q4 2025, Q4 2024, and Q4 2023 respectively.